Docoh
Loading...

HTBX Heat Biologics

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

Company profile

Ticker
HTBX
Exchange
Website
CEO
Jeffrey Wolf
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Heat Biologics I, Inc • Heat Biologics III, Inc. • Heat Biologics IV, Inc. • Heat Biologics GmbH. • Heat Biologics Australia Pty LTD • Zolovax, Inc. • Pelican Therapeutics, Inc. • Skunkworx Bio, Inc. • Scorpion Biological Services, Inc. • Abacus Biotech, Inc. ...
IRS number
262844103

HTBX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 21
19 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 21.57M 21.57M 21.57M 21.57M 21.57M 21.57M
Cash burn (monthly) 3.2M (positive/no burn) 2.24M 2.54M 2.05M 1.91M
Cash used (since last report) 11.64M n/a 8.15M 9.26M 7.47M 6.96M
Cash remaining 9.93M n/a 13.42M 12.31M 14.1M 14.6M
Runway (months of cash) 3.1 n/a 6.0 4.8 6.9 7.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 May 21 Prendergast John K A Common Stock Sell Dispose S No No 5.8655 35,000 205.29K 203,272
4 Jan 21 John J Monahan Stock Options Common Stock Grant Acquire A No No 5.67 65,217 369.78K 65,217
4 Jan 21 Ostrander William L. Stock Options Common Stock Grant Dispose A No No 5.67 51,487 291.93K 51,487
4 Jan 21 Edward B Smith III Stock Options Common Stock Grant Acquire A No No 5.67 65,217 369.78K 65,217
4 Jan 21 Prendergast John K A Common Stock Grant Acquire A No No 0 138,272 0 238,272

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

10.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 41 45 -8.9%
Opened positions 7 21 -66.7%
Closed positions 11 8 +37.5%
Increased positions 12 8 +50.0%
Reduced positions 9 11 -18.2%
13F shares
Current Prev Q Change
Total value 17.92M 19.29M -7.1%
Total shares 2.66M 2.65M +0.4%
Total puts 100.4K 225.4K -55.5%
Total calls 355.3K 193K +84.1%
Total put/call ratio 0.3 1.2 -75.8%
Largest owners
Shares Value Change
Vanguard 1.12M $7.55M +14.5%
BLK Blackrock 479.15K $3.22M -0.6%
Geode Capital Management 217.4K $1.46M +13.2%
PFG Principal Financial Group Inc - Registered Shares 132.57K $892K -12.9%
STT State Street 98.9K $666K +466.5%
MS Morgan Stanley 66.43K $447K +690.8%
Susquehanna International 57.21K $385K -35.9%
IndexIQ Advisors 55.57K $374K -4.2%
NTRS Northern Trust 46.83K $315K +10.4%
Susquehanna Fundamental Investments 45.5K $306K -15.8%
Largest transactions
Shares Bought/sold Change
Vanguard 1.12M +141.94K +14.5%
Qube Research & Technologies 0 -125.07K EXIT
STT State Street 98.9K +81.44K +466.5%
MS Morgan Stanley 66.43K +58.03K +690.8%
HRT Financial 0 -46.5K EXIT
California Public Employees Retirement System 0 -41.31K EXIT
Susquehanna International 57.21K -31.99K -35.9%
Group One Trading 44.42K +29.93K +206.7%
Geode Capital Management 217.4K +25.29K +13.2%
Citadel Advisors 21.2K -24.53K -53.6%

Financial report summary

?
Risks
  • We have a limited operating history conducting commercial development of bioanalytics, process development and manufacturing activities, which may limit the ability of investors to make an informed investment decision.
  • Future sales of our common stock by our existing stockholders could cause our stock price to decline.
Management Discussion
  • Revenues. For the three months ended June 30, 2021 we recognized $0.5 million of grant revenue for qualified expenditures under the CPRIT grant. For the three months ended June 30, 2020, we recognized $0.6 million of grant revenue for qualified expenditures under the CPRIT grant. The decrease in grant revenue in the current-year period primarily reflects the expected timing of completion of deliveries under the current phase of the contracts. As of June 30, 2021, we had a grant receivable balance of $0.4 million for CPRIT proceeds not yet received, but for which the costs had been incurred or the conditions of the award had been met. We continue our efforts to secure future non-dilutive grant funding to subsidize ongoing research and development costs.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: abstract, American, ASCO, baseline, biotherapeutic, built, burden, CDMO, central, compromised, diarrhea, Durham, effort, eliciting, entitled, escalation, event, fatigue, fifteen, fight, franchise, gaining, glycoprotein, half, haplotype, hazard, HR, incompetent, injection, ISR, journal, KTP, led, longer, maculopapular, megabase, mOS, mutation, mutational, NaN, nausea, onsite, poster, pts, quickly, rash, ratio, reaction, remission, replication, ROU, Society, subset, suited, surveillance, tabular, Tech, tenant, trend, undiscounted, unregistered, vivarium
Removed: actively, administration, back, creation, deliver, enrolling, exercisable, extraction, logistical, moment, recruiting, registration, secrete, simplify, submitted